nitazoxanide has been researched along with rifampin in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chaturvedi, V; Roy, KK; Saxena, AK; Sharma, SK; Singh, S; Srivastava, R | 1 |
| Alvala, M; Chandran, M; Jeankumar, VU; Koushik, PV; Salina, EG; Samala, G; Sriram, D; Yogeeswari, P | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Balagopal, A; Sears, CL | 1 |
| Al-Obaidi, I; Batchelor, H; Hoerauf, A; Krome, AK; Kuesel, AC; Opoku, NO; Pfarr, KM; Vaillant, M | 1 |
3 review(s) available for nitazoxanide and rifampin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Clostridium difficile: new therapeutic options.
Topics: Animals; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Community-Acquired Infections; Depsipeptides; Diarrhea; Humans; Nitro Compounds; Polymers; Rifampin; Sulfonic Acids; Thiazoles | 2007 |
The pipeline for drugs for control and elimination of neglected tropical diseases: 2. Oral anti-infective drugs and drug combinations for off-label use.
Topics: Anti-Infective Agents; Doxycycline; Drug Combinations; Fluconazole; Humans; Ivermectin; Neglected Diseases; Off-Label Use; Rifampin | 2023 |
3 other study(ies) available for nitazoxanide and rifampin
| Article | Year |
|---|---|
Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H₃₇Rv.
Topics: Anti-Bacterial Agents; Chemistry Techniques, Synthetic; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Stereoisomerism; Structure-Activity Relationship; Thiazoles | 2011 |
Development of 5-nitrothiazole derivatives: identification of leads against both replicative and latent Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Cell Proliferation; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Thiazoles | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |